Clinical Research Directory
Browse clinical research sites, groups, and studies.
HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)
Sponsor: Université de Sherbrooke
Summary
Primary hyperaldosteronism confers a higher risk of cardiovascular complications compared to essential hypertension. Preliminary data is controversial in regards of excessive maternal fetal and neonatal excessive risks in pregnancy. This study aims at establishing the prevalence of PHA in an population with a recent episode of hypertensive disorder of pregnancy (HDP). The goal is to determine if a universal screening for PHA after a HDP is worthed. The investigators also wish to evaluate the complication rate in pregnant women with PHA compared to women without PHA. This is a prospective cohort study where all eligible women will be screened for PHA after a HDP episode in the last pregnancy. We will then compare PHA women to non PHA women according to pregnancy complications.
Official title: HyperAldosteronism in Pregnancy Predicted Impacts
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2023-01-10
Completion Date
2025-12
Last Updated
2025-01-15
Healthy Volunteers
No
Interventions
Aldosterone/Renin Ratio
Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
Locations (2)
Centre Hopitalier Universiatire de Sherbrooke
Sherbrooke, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada